COVID-19NewsRegulations & Policy

Government launches Mission COVID Suraksha

To accelerate Indian COVID-19 vaccine development

The Government of India has announced the third stimulus package of Rs 900 crore for the Mission COVID Suraksha- The Indian COVID-19 Vaccine Development Mission. This grant will be provided to the Department of Biotechnology (DBT) for Research & Development of Indian COVID-19 vaccines.

THIS CAN BE YOUR ADVERTISEMENT

The COVID-19 Vaccine development Mission with end-to-end focus from preclinical development through clinical development and manufacturing and regulatory facilitation for deployment would consolidate all available and funded resources towards accelerated product development. This will help accelerate the development of approx. five to six vaccine candidates and ensure that these are brought closer to licensure and introduction in the market for consideration of regulatory authorities for introduction in public health systems, to combat further spread of COVID infection.

The important objectives of the fund will be accelerating preclinical and clinical development; licensure of COVID-19 vaccine candidates that are currently in clinical stages or ready to enter the clinical stage of development, establishing clinical trial sites, and strengthening the existing immunoassay laboratories, central laboratories and suitable facilities for animal studies, production facilities and other testing facilities to support COVID-19 vaccine development. The other important objective will be supporting the development of common harmonised protocols, training, data management systems, regulatory submissions, internal and external quality management systems and accreditations.

Capabilities for process development, cell line development and manufacturing of GMP batches for animal toxicology studies and clinical trials will also be supported under the Mission. A key element will be the development of a suitable Target Product Profile so that vaccines being introduced through the mission have preferred characteristics applicable to India.

Led by the Department of Biotechnology and implemented by a dedicated Mission Implementation Unit at Biotechnology Industry Research Assistance Council (BIRAC), the existing activities under National Bio Pharma Mission (NBM) and Ind-CEPI Mission will provide complementary strengths to this Mission.

Phase-I of the COVID Suraksha Mission has been allotted Rs.900 Crore for a period of 12 months.

A total of 10 vaccine candidates have been supported by the Department of Biotechnology so far at both academia and industry and as on date, 5 vaccine candidates are in human trials including the Russian Vaccine Sputnik-V with at least 3 more in advanced stages of preclinical to enter human trials shortly.

Dr Renu Swarup, Secretary Department of Biotechnology, Ministry of Science & Technology and Chairperson BIRAC said, “Mission COVID Suraksha is our targeted effort to enable the development of indigenous, affordable and accessible vaccines for our country and will complement the National Mission of Atmanirbhar Bharat.”

“India has exhibited enormous strength in vaccine manufacturing and through this National COVID Vaccine Mission, we are confident that our vaccine manufacturers will develop affordable and accessible vaccines not only for India but the world,” she added.

PIB

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.

Tags

Related Articles

Leave a Reply

Back to top button
Close
Close